Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioStem TechnologiesBSEM -7.64%36 FCF Margin % is 0.00% as of Sep. 2025. GuruFocus rates BSEM with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 953 Biotechnology companies, BioStem Technologies ranks better than 82.06% on this metric.
The historical data trend for BioStem Technologies's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioStem Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's FCF Margin % distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (BSEM) has a FCF Margin % of 0.00% as of Sep. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #171 out of 953 companies in the Biotechnology industry, placing it in the top 17.9%.
Is BioStem Technologies' FCF Margin % too high?
BioStem Technologies' current FCF Margin % is 0.00%. Based on the distribution chart, BioStem Technologies ranks #171 out of 953 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioStem Technologies has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' FCF Margin % compare to RNTX and SPRO?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #171 out of 953 companies for FCF Margin %. This places BioStem Technologies in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (BSEM) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. BioStem Technologies' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current FCF Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
36GF Score
Get the complete analysis for BSEM
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
